Raltegravir
From Proteopedia
(Difference between revisions)
| Line 40: | Line 40: | ||
! Hepatic - (CYP3A4) | ! Hepatic - (CYP3A4) | ||
|} | |} | ||
| - | <references/> | ||
Revision as of 18:38, 6 December 2010
Pharmacokinetics
| Retroviral Integrase Inhibitor Pharmacokinetics [1][2] | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Parameter | Raltegravir | Elvitegravir | |||||||||
| Tmax (hr) | 1.8 | 2-4 | |||||||||
| Cmax (ng/ml) | 4253 | 2070 | |||||||||
| Bioavailability (%) | 32 | ~30 | |||||||||
| Protein Binding (%) | 83 | N/A | |||||||||
| T1/2 (hr) | 10.8 | 7.6 | |||||||||
| AUC (ng/ml/hr) | 10168 | 21200 | |||||||||
| Dosage (mg) | 400 | 150 | |||||||||
| Metabolism | Hepatic - (UGT1A1) | Hepatic - (CYP3A4) | |||||||||
